Explore our recent stories to see what drives us
Grünenthal’s largest manufacturing investment in the past three decades
Grünenthal operates a robust production network with five manufacturing sites in Germany, Switzerland, Italy, Chile, and Ecuador. These sites produce medicines from Grünenthal's portfolio and offer contract manufacturing services to third parties. Recently, Grünenthal has invested over €80 million into enhancing its production capabilities in Latin America, the largest investment in manufacturing infrastructure in the company’s history. Implementing a standardized approach to product robustness, quality, and regulatory compliance across all its global manufacturing sites, the investment further strengthens production excellence. It contributes to expand the geographical footprint of Grünenthal’s Latin American facilities, ensuring a reliable supply of medicines for patients across Latin America, Europe, and beyond.
“Our investment in Latin America is a strong demonstration of our commitment to delivering high-quality medicine from Latin America to patients around the world.”
Santiago de Chile
Grünenthal has been operating in Santiago de Chile for 45 years. In 2017, a 1,150-square-meter hormone plant was added to the campus, representing the company’s centre of excellence for hormone production and the most modern facility of its kind in Latin America. It delivers high-quality women’s health products to the Chilean market and also provides products for other Latin American markets, including Brazil and Mexico.
Now, a fully refurbished 3,500-square-meter facility will enable a production volume of up to 1.8 billion tablets annually. Featuring state-of-the-art technology, the Santiago campus strengthens Grünenthal’s position among the leading pharmaceutical companies in Chile, providing employees with a cutting-edge working environment with various opportunities for personal development. Grünenthal aims to complete the certification process with the European Medicines Agency (EMA) by November 2025, enabling the supply of medicines from Chile to Europe.
“I am thrilled by the investment in transforming our Santiago site to world-class standards, enabling global patient support. I look forward to the promising future ahead.”
Quito
Grünenthal’s campus in Quito features Ecuador's largest and most modern manufacturing plant for solid, semi-solid, and liquid pharmaceuticals. It is Grünenthal’s central production facility, pharmaceutical development centre, and logistics hub in Latin America.
Our experts in Ecuador can manufacture a variety of formulations such as granules, coated tablets, capsules, liquids, semi-solids and packaging in various blister, sachet or bottle forms. Recognized as a preferred contract manufacturer throughout Latin America, our colleagues serve various multinational corporations.
A new 1,800-square-metre plant will enable the production of up to 300 million high-quality tablets annually to serve pain patients across 17 European countries. It blends into the existing 50,000-square-meter facility. The plant north of Quito guarantees Grünenthal’s high-quality standards. It is certified by various Latin American authorities, such as ANVISA (Brazil) or INVIMA (Colombia). In addition, it is one of the few facilities in Latin America licensed to export to Europe and the only one in Ecuador with an EU Good Manufacturing Practice certificate.
“Our plant exemplifies high-quality pharmaceutical production from Latin America. I am proud of my colleagues, who live up to this standard every day.”
Interested in our Contract Manufacturing services?
Meet our colleagues from Grünenthal PRO (5F119 and 5F123) and Partnering Business (10G55) at this years CPHI in Milan. Contact us to fix appointments.